Obesity levels in the UK may have peaked and could start dropping ‘significantly’ in 2025 due to weight loss jabs, according ...

As usage of the medications increases, Circana research indicates deli and produce could be bright spots for spending.

This is the web edition of D.C. Diagnosis, STAT’s twice-weekly newsletter about the politics and policy of health and ...

The evolution of AI, more limited-time product offerings and GLP-1 use for weight loss are among the issues expected to play a more prominent role this year.

The New Year is a time of reflection and change for many Americans, who start each January with a clean slate and goals for the next 12 months.Many resolutions ...

Holiday weight gain hits home for many come January. These days, folks making resolutions to slim down and get fit have an ...

Medicare drug plans can now cover Eli Lilly & Co.'s obesity drug Zepbound as a treatment for obstructive sleep apnea, news that's expected to prove a big boost for the drug company.

Eli Lilly's obesity drug Zepbound can now be covered by government-backed Medicare insurance plans for use in sleep apnea, ...

Sharon Mann has lost nearly 30 pounds since starting on Mounjaro, a GLP-1 medication. Dr. Sanjay Gupta reports.

Roche's strategic acquisition of Poseida Pharmaceuticals positions them as a leader in the allogeneic cell therapy market.

Medspas are leading the charge in offering GLP-1 treatments, with 60% of medspas in the U.S. now providing these services, compared to 35% of aesthetic physician offices. Average spend per patient ...

Diet food brands have been hit in recent years, but now GLP-1 drugs like Ozempic are hitting the market, will this spell the ...